Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report)’s stock price dropped 4% on Tuesday . The stock traded as low as $2.73 and last traded at $2.90. Approximately 8,597 shares changed hands during mid-day trading, an increase of 297% from the average daily volume of 2,165 shares. The stock had previously closed at $3.02.
Graybug Vision Stock Performance
The firm has a market capitalization of $4.56 million, a PE ratio of -1.68 and a beta of 1.20. The stock’s 50-day simple moving average is $3.17 and its 200-day simple moving average is $3.91.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
See Also
- Five stocks we like better than Graybug Vision
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Effectively Use the MarketBeat Ratings Screener
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
